Citigroup Inc Pharvaris N.V. Transaction History
Citigroup Inc
- $190 Billion
- Q1 2025
A detailed history of Citigroup Inc transactions in Pharvaris N.V. stock. As of the latest transaction made, Citigroup Inc holds 543 shares of PHVS stock, worth $9,556. This represents 0.0% of its overall portfolio holdings.
Number of Shares
543
Previous 543
-0.0%
Holding current value
$9,556
Previous $10,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding PHVS
# of Institutions
50Shares Held
39.1MCall Options Held
0Put Options Held
0-
General Atlantic LLC New York, NY7.53MShares$133 Million3.99% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA4.41MShares$77.6 Million78.82% of portfolio
-
Ven Bio Partners LLC San Francisco, CA4.29MShares$75.5 Million72.08% of portfolio
-
Viking Global Investors LP3.65MShares$64.3 Million0.19% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA3.3MShares$58.1 Million17.41% of portfolio
About Pharvaris N.V.
- Ticker PHVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,766,000
- Market Cap $594M
- Description
- Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...